Chemours Company (CC) Stock Falls on Q4 2025 Earnings

Chemours Company (The) (CC) reported fourth-quarter 2025 revenue of $1.33 billion, down 2.1% year over year and missing the consensus estimate of $1.37 billion.

Revenue: $1.33 billion (‑2.1% YoY; estimate $1.37 billion).

Cost of sales: $1.17 billion (+8.2% YoY).

Gross profit: $156 million (‑42.9% YoY).

Operating profit: ‑$61 million (down 213.0% YoY).

Net income attributable to common shareholders: ‑$61 million (down 1,625.0% YoY).

Diluted earnings per share came in at ‑$0.31, well below the estimate of $0.07. The stock reacted sharply, with a decline of 12.74% since market close.

Cash from operating activities: ‑$127 million (down 192.0% YoY).

Purchases of property, plant and equipment: $168 million (down 254.1% YoY).

Cash and cash equivalents: $670 million (down 6.0% YoY).

Total liabilities: $7.13 billion (up 3.0% YoY).

Overall, Chemours (CC) showed modest revenue decline but significant margin compression and a swing to operating and net losses, accompanied by negative operating cash flow and elevated capital spending.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Chemours Company (The) Hedge Fund Activity

We have seen 183 institutional investors add shares of Chemours Company (The) stock to their portfolio, and 235 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

APPIAN WAY ASSET MANAGEMENT LP removed 2,890,685 shares (-75.8%) from their portfolio in Q3 2025, for an estimated $45,788,450
MILLENNIUM MANAGEMENT LLC removed 2,252,307 shares (-50.1%) from their portfolio in Q4 2025, for an estimated $26,554,699
LUMINUS MANAGEMENT LLC removed 1,407,020 shares (-79.7%) from their portfolio in Q4 2025, for an estimated $16,588,765
MOORE CAPITAL MANAGEMENT, LP removed 1,279,340 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $20,264,745
MARSHALL WACE, LLP removed 1,254,855 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $14,794,740
AMERICAN CENTURY COMPANIES INC added 1,237,283 shares (+52.0%) to their portfolio in Q4 2025, for an estimated $14,587,566
UBS GROUP AG removed 1,169,293 shares (-24.6%) from their portfolio in Q4 2025, for an estimated $13,785,964

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Chemours Company (The) Analyst Ratings

Wall Street analysts have issued reports on $CC in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

UBS issued a "Buy" rating on 11/11/2025
RBC Capital issued a "Outperform" rating on 11/10/2025
Truist Securities issued a "Buy" rating on 11/10/2025
Mizuho issued a "Outperform" rating on 10/16/2025

To track analyst ratings and price targets for Chemours Company (The), check out Quiver Quantitative's $CC forecast page.

Chemours Company (The) Price Targets

Multiple analysts have issued price targets for $CC recently. We have seen 5 analysts offer price targets for $CC in the last 6 months, with a median target of $18.0.

Here are some recent targets:

Peter Osterland from Truist Securities set a target price of $21.0 on 01/21/2026
Jeffrey Zekauskas from JP Morgan set a target price of $13.0 on 12/03/2025
Joshua Spector from UBS set a target price of $18.0 on 11/11/2025
Arun Viswanathan from RBC Capital set a target price of $17.0 on 11/10/2025
John Roberts from Mizuho set a target price of $18.0 on 10/16/2025